摘要
目的探讨局限性晚期前列腺癌间歇性内分泌治疗的效果。方法选取局限性晚期(T3a、T3b)前列腺癌患者24例,全雄性激素阻断治疗6～9个月,停药时机为PSA≤0.2ng/ml后,持续3～6个月,以后根据每月PSA的检测结果决定是否再行内分泌治疗。治疗期及间歇期检测血清睾酮值,并行生活质量评分。结果24例患者间歇性内分泌治疗6个月后血清PSA均降至正常,前列腺体积明显缩小。第一至第四疗程的平均间歇期分别为5.2、5.6、5.4和2.7个月。最低PSA值从第一疗程0.1ng/ml上升至第四疗程的1.5ng/ml。93.1%的患者在第1个间歇期睾酮回升至正常值上限,中位回升时间为12.3周。83.3%的患者完成2个周期的治疗,37.5%的患者完成3个周期的治疗,4.2%的患者进入到第4个周期的治疗,随访时间0.5～3.5年。生活质量评分显示,患者性趣、排尿症状和肠道症状等在间歇期得到显著改善。结论间歇性内分泌治疗是治疗局限性晚期前列腺癌的有效手段。
Objective To investigate the efficacy of the intermittent hormonal therapy（IHT）in the treatment of local late-stage prostate cancer. Methods The IHT was employed to 24 cases of local late-stage prostate cancer with the clinical staging of T3a or T3b. Specifically,maximal andro-gen bloekade（MAB） therapies have been employed for six to nine months,and then stopped until the serum PSA was decreased below 0.2 ng/ml, which were lasting for three to six months. The month test level of PSA decided whether or not further MAB is needed. During the treatment and intermittent,serum testosterone level and quality of life score were evaluated periodically. Results All of PSA levels of the patients were reduced to normal,accompanied by a reduced significant prostate volume. First to the fourth course of treatment, the average interval time were 5.2,5.6,5.4 and 2.7 months respectively. The lowest PSA value went ut3 from the first course of 0.1 ng/ml to the fourth course of 1.5 ng/ml. 93.1% of patients at the first period of an intermittent testosterone were reduced to normal,with a median recovery time of 12.3 weeks. 83.3% of patients had completed 2 cycles of IHT, 37.5% had completed 3 cycles, 4.2% had came into the fourth cycle,as follow-up for 0.5 to 3.5 years. The quality of life score showed the urinary symptoms,bowel symptoms and sexual intend at the interim period have been significantly improved. Conclusions IHT is an effeetive approach for the therapy in treating local late-stage prostate cancer.
出处
《现代泌尿生殖肿瘤杂志》
2009年第2期78-80,共3页
Journal of Contemporary Urologic and Reproductive Oncology
